Alzheimer’s Disease and Memantine
Alzheimer’s Disease and Memantine
Alzheimer’s disease is the most common neurodegenerative disorder and a leading cause of dementia in aging populations. The condition triggers a cascade of pathological processes that result in signaling pathway disruption, impaired neurotransmission, and eventual neuronal loss. Memantine (Aladdin M107928 ≥98% ) is used clinically to help slow the progression of this disease.
While many neuroprotective drugs act by enhancing cholinergic transmission to improve cognitive performance, memantine works differently—it is a noncompetitive antagonist of NMDA receptors, reducing glutamatergic signaling. By blocking excessive calcium ion influx through extrasynaptic NMDA receptors, memantine helps limit excitotoxic neuronal damage.
Memantine also interacts with other ligand-gated ion channels, including nicotinic acetylcholine receptors (nAChRs), dopamine receptors, and serotonin receptors. Although these interactions contribute little to its cognitive benefits, they may underlie additional effects such as antidepressant, antitussive, and analgesic (antinociceptive) activity.
At therapeutic concentrations, memantine supports synaptic plasticity and maintains or improves memory function in animal models of Alzheimer’s disease. It also offers neuroprotection against excitotoxic degeneration. Research further indicates that memantine can mitigate amyloid-β (Aβ)–induced toxicity and may influence APP processing, potentially reducing Aβ production.
References:
Reisberg B, Doody R, Stöffler A, et al. New Engl. J. Med. 2003;348(14):1333–41.
Cacabelos R, Takeda M, Winblad B. Int J Geriatr Psychiatry. 1999 Jan;14(1):3–47.
Nakaya K, Nakagawasai O, Arai Y, et al. Behav Brain Res. 2011 Mar 17;218(1):165-73.
Pringle A, Parsons E, Cowen LG, et al. J Psychopharmacol. 2012 Nov;26(11):1417-23.
Dicpinigaitis PV, Canning BJ, Garner R, et al. J Pharmacol Exp Ther. 2015 Mar;352(3):448-54.
Kayser V, Latrémolière A, Hamon M, et al. Eur J Pain. 2011 May;15(5):451-8.
Colom LV, Castaneda MT, Aleman D, et al. Neurosci Lett. 2013 Apr 29;541:54-7.
Aladdin: https://www.aladdinsci.com/